Abstract-Angiotensin-(1-7) has been suggested to be a novel vasodilating peptide. We investigated the direct vascular effect of angiotensin-(1-7) in human forearm resistant vessels, particularly with regard to the interaction with angiotensin II, in healthy normotensive men by strain-gauge venous occlusion plethysmography with intra-arterial infusions of peptides. Intra-arterial infusion of angiotensin-(1-7) at 0.1 to 2000 pmol/min did not cause vasodilatation but rather reduced forearm blood flow by Ϸ10% at the highest dose. A placebo-controlled study showed that angiotensin-(1-7) at 0.5 to 40 nmol/min caused weak but significant vasoconstriction (Pϭ0.0016 by ANOVA). Angiotensin-(1-7) at 100 pmol/min, but not at 10 pmol/min, significantly shifted the angiotensin II dose-response curve toward the right (meanϮSD of percent changes in forearm blood flow: Ϫ19Ϯ17%, Ϫ33Ϯ22%, Ϫ55Ϯ12%, Ϫ63Ϯ10%, and Ϫ68Ϯ5% at 5, 10, 25, 50, and 100 pmol/min of angiotensin II, respectively, with saline; 5Ϯ13%, 0.9Ϯ18%, Ϫ40Ϯ16%, Ϫ54Ϯ9%, and Ϫ61Ϯ6% with angiotensin-(1-7), Pϭ0.0021 by ANOVA). Angiotensin-(1-7) did not affect the dose-response curve of noradrenaline [3Ϯ12%, 5Ϯ16%, Ϫ20Ϯ22%, Ϫ31Ϯ18%, and Ϫ40Ϯ12% at 25, 50, 100, 300, and 600 pmol/min of noradrenaline, respectively, with saline; Ϫ4Ϯ15%, Ϫ2Ϯ23%, Ϫ29Ϯ22%, Ϫ34Ϯ16%, and Ϫ42Ϯ9% with angiotensin-( 
I t has been suggested that angiotensin-(1-7) [Ang-(1-7)]
, which is one of bioactive components of the renin-angiotensin system and reportedly formed from angiotensin I (Ang I) and angiotensin II (Ang II), 1,2 is a novel vasodilating peptide. Release of nitric oxide, 3 production of prostaglandins, 4, 5 and potentiation of effect of bradykinin 6, 7, 8 by Ang-(1-7) have been postulated as possible mechanisms for vasodilatation. Ang-(1-7) is also thought to contribute to a reduction in blood pressure after the blockade of the reninangiotensin system. 9 -11 However, the subtype of angiotensin receptors involved in the vascular effect of Ang-(1-7) remains unknown. Benter et al 12 failed to inhibit the hypotensive effect of Ang-(1-7) in pithed rats by either angiotensin type 1 (AT 1 ) or type 2 (AT 2 ) receptor antagonists. On the other hand, Mahon et al 13 showed no vasodilating effect of Ang-(1-7) itself but significant attenuation of Ang II-induced vasoconstriction by a relatively low dose of Ang-(1-7) possibly via an AT 1 receptor. Therefore, Ang-(1-7) appears to have 2 different vascular effects that are mediated through the different subtypes of angiotensin receptors.
The vascular effect of this peptide has not been documented well in humans. Unlike results from animal studies, a human study by Kono and colleagues 14 showed increased blood pressure during intravenous Ang-(1-7) infusion at a comparable dose as that in the animal studies that showed a hypotensive effect. This is not surprising because Ang-(1-7) has been known to have a weak agonistic effect. 15, 16 In fact, a short-term pressor effect has been demonstrated in pithed rats. 11 However, interspecies differences in the response to Ang-(1-7) may also exist. We investigated the direct vascular effect of Ang-(1-7), particularly with regard to the interaction with Ang II, in human resistant vessels in vivo.
Methods Subjects
Twenty-two healthy normotensive men (8 for protocol 1, 6 for protocol 2, and 8 for protocol 3) were recruited for the present study. All subjects underwent normal routine physical and laboratory examinations. Written informed consent was obtained from each subject after a full explanation of the study. All study protocols were approved by the Yokohama City University Hospital Ethics Committee.
Forearm Blood Flow Measurement
All experiments were performed in a quiet, temperature-controlled room. After an overnight fast, all subjects attended our Clinical Research Unit on the study day. Subjects abstained from cigarettes, alcohol, and caffeine-containing drinks for Ն12 hours before the study. Forearm blood flow was measured by bilateral strain-gauge venous occlusion plethysmography. The details of the method and the reproducibility of the measurement were described elsewhere. 17, 18 Briefly, pediatric cuffs placed around wrists were inflated to 200 mm Hg during each measurement. Collecting cuffs placed around the upper arms were inflated to 40 mm Hg and deflated every 15 seconds. Strain gauges were placed around the forearms 5 cm distal to the olecranon. All drugs were infused into the catheter inserted into the brachial artery of the nondominant arm under local anesthesia with 1% lidocaine. The infusion rate was maintained at 1 mL/min throughout the study unless otherwise indicated. 
Protocol 3: Effect of Ang-(1-7) on Vasoconstriction Induced by Ang II and Noradrenaline
Eight subjects (BMI 22.0Ϯ2.7 kg/m 2 , age 20 to 25) received noradrenaline (25, 50, 100, 300, and 600 pmol/min, at 10 minutes per dose) (Sankyo) and Ang II (5, 10, 25, 50, and 100 pmol/min, at 10 minutes per dose) (Yamanouchi) intra-arterially with concomitant intra-arterial infusions of Ang-(1-7) at 10 pmol/min, 100 pmol/min, or placebo (isotonic saline) on 3 study days in a double-blind, crossover fashion. There was a washout period for 30 minutes between Ang II and noradrenaline. The order of these 2 vasoconstrictors was randomized but kept the same in the same subject.
Analysis of Forearm Blood Flow Data
All forearm blood flow data were obtained via a Mac Laboratory 4 chart recorder (AD instruments). The percentage change in ratio of forearm blood flow from baseline was calculated as [
. F(i) and F(ni) represent forearm blood flow in the infused arm and noninfused arm, respectively, during baseline measurement (B) and drug infusion (D).
Statistical Analysis
Data are shown as meanϮSD unless otherwise indicated. Comparison between changes in forearm blood flow with infusions of Ang-(1-7) and saline (protocol 2) was made by repeated measure of ANOVA. Comparison between changes in forearm blood flow during Ang II and noradrenaline infusion with concomitant infusions of Ang-(1-7) or saline was made by repeated measure of ANOVA, ie, interaction between treatment [Ang- (1) (2) (3) (4) (5) (6) (7) or placebo] and the doses of agonists. Figure 1 shows forearm blood flow during the infusion of Ang-(1-7) at various doses. There were no significant changes in forearm blood flow at 0.5 to 250 pmol/min of Ang-(1-7). Forearm blood flow during infusions of Ang-(1-7) at 500 to 2000 pmol/min tended to be reduced but the changes did not reach statistical significance. ) and between before noradrenaline with saline and with Ang-(1-7) (2.64Ϯ0.76 versus 2.58Ϯ0.53 mL ⅐ min Ϫ1 ⅐ dL
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Ϫ1
). The magnitude of reduction of forearm blood flow by Ang II infusion was significantly attenuated by the infusion of Ang-(1-7) at 100 pmol/min [percent changes in forearm blood flow; Ϫ19Ϯ17%, Ϫ33Ϯ22%, Ϫ55Ϯ12%, Ϫ63Ϯ10%, and Ϫ68Ϯ5% at 5, 10, 25, 50, and 100 pmol/min of Ang II with saline; 5Ϯ13%, 0.9Ϯ18%, Ϫ4Ϯ16%, Ϫ54Ϯ9%, and Ϫ61Ϯ6% with Ang-(1-7) at 100 pmol/min, Pϭ0.0021, by ANOVA, placebo versus 100 pmol/min of Ang-(1-7)] but not at 10 pmol/min. Ang-(1-7) infusion at either 10 pmol/min or 100 pmol/min did not affect the noradrenaline dose-response curve.
Discussion Is Ang-(1-7) a Vasodilating Peptide?
We demonstrated that the intra-arterial infusion of Ang-(1-7) itself had no direct vasodilating effect, at least at the doses that we used in human forearm resistant vessels. Ang-(1-7) caused weak but significant vasoconstriction at the high doses. The forearm concentration of Ang-(1-7) in our study (protocol 2) was assumed to be 2 to 3 mol/L at the highest dose (40 nmol/min), which was almost the same as the concentration that caused 50% vasorelaxation in canine coronary arteries (2.7 mol/L) 19 and in porcine coronary arteries (2.2 mol/L). 3 Thus, our results are the antithesis of several previous reports that showed the direct vasodilating effect of Ang-(1-7) in isolated arteries 3, 19 and in vivo hypotensive effect. 12, 20 However, there has not necessarily been universal agreement with the vasodilating property of this peptide. Abbas et al 8 showed that Ang-(1-7) at 20 to 380 nmol/rat had an angiotensin type 1 (AT 1 ) receptor-mediated hypertensive effect unless exogenous bradykinin was administrated. This suggests that the vasodilating effect of Ang-(1-7) may require sufficient bradykinin. Kono and colleagues 14 showed the hypertensive effect of Ang-(1-7) at 18 nmol ⅐ kg Ϫ1 ⅐ min Ϫ1 for 15 minutes, which was comparable with the dose used in the study by Abbas et al, in normotensive healthy subjects. These various vascular and blood pressure responses to Ang-(1-7) among studies may result in part from methodological differences. Different vascular beds (eg, forearm vessels versus coronary artery) from different species (rat versus human) may have different responses to Ang- (1-7) . The duration of infusion of Ang-(1-7) might also affect the result. Indeed, Benter et al 12 demonstrated a biphasic acute blood pressure response to Ang-(1-7), which consisted of an initial pressor component and a subsequent depressor component after a bolus injection of Ang-(1-7) at 300 nmol/rat in rats.
Interaction With Ang II
The present study also demonstrated that Ang-(1-7) significantly and dose dependently attenuated vasoconstriction evoked by Ang II but not by noradrenaline. This result raises the possibility that Ang-(1-7) may be an endogenous antagonist of AT 1 receptor although the concentration of Ang-(1-7) in the forearm vascular beds (0.01 mol/L) during the infusion at 100 pmol/min was much lower than IC 50 (Ͼ1 mol/L) for AT 1 receptor. 21 Interestingly, Mahon et al 13 showed a significant rightward shift of the dose-response curve of Ang II by Ang-(1-7) in rabbit aortic rings and attenuation of the pressor response to Ang II by Ang-(1-7) in rats, whereas the administration of Ang-(1-7) itself had no hypotensive effect. Because this effect was observed specifically with Ang II, but not with other vasoconstrictors, and was reversed by losartan, they speculated that Ang-(1-7) modulated the effect of Ang II via the AT 1 receptor. Our results are consistent with their report. There are, however, several other possible mechanisms for Ang-(1-7) mediated attenuation of the vascular effect of Ang II. Evidence suggests that Ang-(1-7) stimulates releases of vasodilating prostaglandin 4, 5 and NO 3 and also potentiates the effect of bradykinin. [6] [7] [8] Although this effect has not been confirmed in human vessels, these agents could attenuate the vascular effect of Ang II. 22, 23 This, however, may not be the case for our results, because these vasodepressor agents must affect the effect of noradrenaline as well. 24, 25 Therefore, albeit no experiment with angiotensin receptor antagonists was conducted in our study, we speculate that Ang-(1-7) attenuated the vascular action of Ang II via the AT 1 receptor. Experiments to investigate the interaction among Ang-(1-7), and Ang II, AT 1 receptor antagonist and inhibitors of prostaglandins, nitric oxide, and bradykinin in man are clearly warranted to confirm this hypothesis. One would claim that Ang-(1-7) should show direct vasodilating effect if it has an AT 1 receptor antagonistic effect. However, evidence suggests that Ang II does not contribute to maintaining vascular tone in salt-repleted healthy subjects. 26 Therefore, it is not surprising that Ang-(1-7) alone has no vasodilating effect on our subjects.
Two different mechanisms seem at work for the vascular effect of Ang-(1-7) . First through the AT 1 receptor directly and second through the production of vasodilating agents that might involve non-AT 1 and AT 2 angiotensin receptor(s). In contrast to our study, Benter et al 27 showed nonspecific effect of Ang- (1-7) , ie, pressor responses to not only Ang II but also phenylephrine, was attenuated by the chronic administration of Ang-(1-7) in spontaneously hypertensive rats. This nonspecific vasodilating effect of Ang-(1-7) may be explained by stimulated production of vasodepressor agents by Ang- (1-7) .
Are These Results Physiologically or Pathophysiologically Significant?
Our study showed that the vascular effects of Ang II at 2.5 to 5 nmol/L was inhibited by Ang-(1-7) at 10 nmol/L. 28 Therefore, although the concentration of Ang-(1-7) in this study was 1000ϫ higher than the physiological concentration in man (10 pmol/L), the ratio of the concentration of Ang II to Ang-(1-7) was 0.25 to 0.5, which could be seen after ACE inhibition. 28, 29 The hypotensive effect of ACE inhibitors was not necessarily associated only with reduction in plasma Ang II levels. 30 Increased Ang-(1-7) after ACE inhibition may, at least in part, contribute to effect of ACE inhibitors by attenuation of the effect of Ang II. Our results also suggest that Ang-(1-7) might work as an endogenous Ang II antagonist in the presence of high Ang II from the activated renin-angiotensin system, whereas Ang-(1-7) appears to be, as shown in protocol 1 and 2, weak Ang II in salt-repleted subjects with normal or inhibited renin-angiotensin system. Ang-(1-7), therefore, can be regarded as a counterregulatory peptide to Ang II in patients with high-renin activity, such as patients with heart failure and renovascular hypertension. Thus, the roles of Ang-(1-7) in these cardiovascular diseases should be investigated.
Conclusion
We conclude that Ang-(1-7) itself does not have a vasodilating effect, at least at the dose that we used, but attenuates vasoconstriction evoked only by Ang II in human forearm resistance vessels. Thus, Ang-(1-7) is supposed to act as an endogenous angiotensin receptor antagonist and might be physiologically relevant when the renin-angiotensin system is activated.
